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ABSTRACT 
 Polyhexamethylene biguanide (PHMB) is a 
broad spectrum antimicrobial agent. Used 
widely within Europe and the US in a myriad 
of applications from swimming pools to 
contact lens solutions. However its use as a 
topical application for wound care has not 
been widely adopted – especially within the 
UK. A literature clinical evaluation was 
conducted in accordance with the Medical 
Device Directive and database results were 
screened and abridged based on GHTF 
quality criteria. The resulting clinical 
information was extracted and reviewed.  
 
The evidence demonstrates PHMB to have 
excellent bacteriocidal properties whilst 
offering very low toxicity in humans, does 
not causes skin sensitivity in normal 
concentrations. Furthermore there is no 
evidence of bacterial resistance, and is highly 
biocompatible. It was clear that PHMB offers 
an excellent tool to clinicians in both 
preventing and treating infected wounds.  
  
 
 
 
 
Background 
 
Chronic wounds  
• Cost the NHS around £3bn every year, 
Affect 200,000 individuals at any one time.  
• Bacterial colonisation are both complex 
and controversial. 
• Once bacterial colonisation is established, 
wound healing is significantly reduced, or 
halted exacerbating the pain, discomfort 
and reduced quality of life for patients. 
 
Polyhexamethylene biguanide (PHMB) is a 
cationic biocide which binds to negatively 
charged phosphate groups of bacterial 
phospholipid walls. This in turn disrupts the 
membrane, causing cytoplasmic shedding and 
cell death. However due to this selection and 
similarity to our own Antimicrobial Peptides 
(AMPs) means it leaves mammalian cells 
intact.  
 
Used extensively for over 60 years, PHMB is 
used in 
• contact lens solutions,  
• swimming pools, 
• wound irrigation solutions,  
• eye washes in the treatment of 
acanthamoeba keratitis.   
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods 
A literature clinical evaluation was conducted 
in accordance with EU Directive 93/42/EEC 
(medical device directive), and guidelines 
from MEDDEV and Global Harmonisation Task 
Force (GHTF).  
 
A literature search review plan was created 
detailing: 
o Database selection 
o Search terms (for each database) 
o Characteristics  
• must contain PHMB,  
• delivery vehicle (e.g. foam, 
cellulose or gauze) 
• used in wound care (any 
aetiology) 
 
An exclusion criterion was then defined to 
shortlist potential literature. Using three 
phases below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Papers undergoing phase 3 were scored based 
on the quality and relevance using the GHTF 
scoring system.  An example of the data 
extraction form is shown below (table1) 
   
 
 
 
 
 
 
 
 
 
 
 
Results 
The largest search results came from Google 
Scholar with 3290 articles from the initial 
search, and 78 from EBSCOhost (which 
included PubMed, CINHAL etc.).  
 
Table 2 shows the proportion of search results 
making it to phase 3. 
Table 3 shows the results of the phase reviews 
shown as a 100% stacked bar chart  
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
A number of key conclusions can be drawn 
from the systematic review of current 
literature, as it relates to PHMB in wound 
care. 
 
• PHMB has been in use for 60 years within 
Europe & US 
 
• Similarity with antimicrobial peptides 
means it kills bacteria leaving mammalian 
cells intact 
 
• Effective on bacteria, viruses, fungi, yeasts. 
 
• No evidence of bacterial resistance 
 
• Very low toxicity 
 
• Non-sensitising 
 
• Highly biocompatible (outperforms 
chlorhexidine, iodine, triclosan, silver) 
  
 
Based on all the information in the current 
literature, and the absence of any adverse 
events reported, it would be sensible to 
conclude that PHMB offers a safe alternative 
to current topical therapies.  
 
• PHMB offers an opportunity to incorporate 
a new method of bacterial control which 
has been proven to be safe, efficient and 
cost effective.  
 
• Useful in both the treatment and 
prevention of wound colonisation.  
 
• The use of PHMB in wound dressings 
provides huge benefits to patients, and 
provides clinicians with an effective tool. 
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Table 1: Example of literature data extraction 
Image1: PHMB structure 
Phase 1 
• Review title only 
Phase 2 
• Review abstract 
Phase 3 
• Review full text 
• Extract data 
Database Phase 3 Actual 
EBSCOhost 46% n=36/78 
Google Scholar 3% n=86/3290 
MHRA/MAUDE 0% n=0/2 
Cochrane 0% n=0/1 
NHS CRN/CT 6% n=1/18 
BSI 0% n=0/20 
Table 2: Proportion of articles making it to phase 3 review. 
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Table 3: Results of literature screen (100% stacked) 
